ECSP10010646A - Derivados de espiro-indol para el tratamiento de enfermedades parasitarias - Google Patents

Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Info

Publication number
ECSP10010646A
ECSP10010646A EC2010010646A ECSP10010646A ECSP10010646A EC SP10010646 A ECSP10010646 A EC SP10010646A EC 2010010646 A EC2010010646 A EC 2010010646A EC SP10010646 A ECSP10010646 A EC SP10010646A EC SP10010646 A ECSP10010646 A EC SP10010646A
Authority
EC
Ecuador
Prior art keywords
treatment
plasmodium
espiro
indol
derivatives
Prior art date
Application number
EC2010010646A
Other languages
English (en)
Inventor
Bryan K S Yeung
Philipp Krastel
Shi Hua Ang
Seh Yong Leong
Liying Jocelyn Tan
Wei Lin Josephine Wong
Bin Zou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40613087&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010646(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010646A publication Critical patent/ECSP10010646A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invencion se refiere a compuestos organicos, los cuales tienen propiedades farmaceuticas interesantes. En particular, los compuestos son ·tiles en el tratamiento y/o la prevencion de infecciones tales como aquellas causadas por Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi y parasitos del genero Leishmania, tales como, por ejemplo, Leishmania donovani. La invencion tambien se refiere a composiciones farmaceuticas que contienen los compuestos, asi como a los procesos para su preparacion.
EC2010010646A 2008-04-29 2010-11-29 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias ECSP10010646A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08155342 2008-04-29
EP09151117 2009-01-22

Publications (1)

Publication Number Publication Date
ECSP10010646A true ECSP10010646A (es) 2010-12-30

Family

ID=40613087

Family Applications (2)

Application Number Title Priority Date Filing Date
EC2010010646A ECSP10010646A (es) 2008-04-29 2010-11-29 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
ECIEPI201768127A ECSP17068127A (es) 2008-04-29 2017-10-13 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECIEPI201768127A ECSP17068127A (es) 2008-04-29 2017-10-13 Derivados de espiro-indol para el tratamiento de enfermedades parasitarias

Country Status (30)

Country Link
US (2) US8053442B2 (es)
EP (2) EP2285808B1 (es)
JP (2) JP5438098B2 (es)
KR (1) KR101390081B1 (es)
CN (1) CN102015711B (es)
AR (1) AR071222A1 (es)
AU (1) AU2009242279B2 (es)
BR (1) BRPI0911577B8 (es)
CA (1) CA2719365C (es)
CL (1) CL2009001007A1 (es)
CO (1) CO6300940A2 (es)
CY (1) CY1114874T1 (es)
DK (1) DK2285808T3 (es)
EA (1) EA019601B1 (es)
EC (2) ECSP10010646A (es)
ES (1) ES2447590T3 (es)
HR (1) HRP20140151T1 (es)
IL (1) IL208357A (es)
JO (1) JO2904B1 (es)
MA (1) MA32316B1 (es)
MX (1) MX2010011868A (es)
MY (2) MY156601A (es)
NZ (1) NZ588217A (es)
PE (1) PE20091787A1 (es)
PL (1) PL2285808T3 (es)
PT (1) PT2285808E (es)
SI (1) SI2285808T1 (es)
TW (1) TWI442921B (es)
WO (1) WO2009132921A1 (es)
ZA (1) ZA201006752B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases
CN102584835B (zh) * 2011-01-17 2014-08-27 苏州大学 一种含吲哚结构的螺杂环化合物及其制备方法
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
EP3578557B1 (en) * 2012-03-23 2023-09-20 Novartis AG Chemical process for preparing spiroindolones and intermediates thereof
CN106232619B (zh) 2013-11-13 2022-09-09 科德克希思公司 工程化的亚胺还原酶和用于酮和胺化合物的还原胺化的方法
CN107002050A (zh) 2014-11-25 2017-08-01 科德克希思公司 工程化亚胺还原酶和用于酮和胺化合物的还原胺化的方法
TWI784255B (zh) 2014-12-18 2022-11-21 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
ES2754803T3 (es) * 2015-01-23 2020-04-20 Glaxosmithkline Ip Dev Ltd Derivado de pirazolo[3,4-dpirimidina y su uso para el tratamiento de leishmaniasis
WO2016147205A1 (en) * 2015-03-13 2016-09-22 Council Of Scientific & Industrial Research Novel substituted 3-spirophosphoryl pyrazole-2-oxindoles as anti-infectives and process for the synthesis thereof
WO2016201440A1 (en) * 2015-06-12 2016-12-15 The Regents Of The University Of California Spiroindolinones and therapeutic uses thereof
JP2017024992A (ja) * 2015-07-15 2017-02-02 公益財団法人微生物化学研究会 化合物の製造方法
LT3810283T (lt) 2018-06-21 2023-08-25 F. Hoffmann-La Roche Ag 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti
CN110590795B (zh) * 2019-10-10 2021-01-22 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一类多并杂环螺羟吲哚类化合物的合成方法
US20230132973A1 (en) * 2020-03-17 2023-05-04 The University Of Buea DIHYDRO-SPIRO[INDOLINE-3:1'-iSOQUINOLIN]-2-ONES AS ANTIMALARIAL AGENTS
CN116273188B (zh) * 2023-03-01 2024-06-25 岭南师范学院 一种负载金属的多孔有机框架材料在催化Pictet-Spengler反应中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663935A1 (fr) * 1990-06-27 1992-01-03 Adir Nouveaux 1,2,3,4,5,6-hexahydroazepino [4,5-b] indoles et 1,2,3,4-tetrahydrobethacarbolines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
NZ509324A (en) * 1998-07-14 2003-07-25 Bayer Ag Antiparasitic artemisinin derivatives (endoperoxides)
BR9916371A (pt) 1998-12-19 2001-09-18 Janssen Pharmaceutica Nv Composto de espiro anti-histamìnico
US20050137220A1 (en) * 2003-07-23 2005-06-23 Pharmacia Corporation Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
CN101547923A (zh) 2006-12-07 2009-09-30 弗·哈夫曼-拉罗切有限公司 作为via受体拮抗剂的螺环-哌啶衍生物
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2285808B1 (en) * 2008-04-29 2013-11-20 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases

Also Published As

Publication number Publication date
CN102015711A (zh) 2011-04-13
MA32316B1 (fr) 2011-05-02
WO2009132921A1 (en) 2009-11-05
MX2010011868A (es) 2010-11-26
PT2285808E (pt) 2014-02-24
EP2285808A1 (en) 2011-02-23
JP2011518852A (ja) 2011-06-30
NZ588217A (en) 2012-10-26
HRP20140151T1 (hr) 2014-03-28
AU2009242279B2 (en) 2012-08-30
CA2719365A1 (en) 2009-11-05
PL2285808T3 (pl) 2014-04-30
TW200948357A (en) 2009-12-01
IL208357A (en) 2014-11-30
DK2285808T3 (da) 2014-02-03
CL2009001007A1 (es) 2010-06-11
JP5438098B2 (ja) 2014-03-12
BRPI0911577A8 (pt) 2018-03-06
EP2722333A1 (en) 2014-04-23
US20090275560A1 (en) 2009-11-05
EA019601B1 (ru) 2014-04-30
JP2014065729A (ja) 2014-04-17
AR071222A1 (es) 2010-06-02
ES2447590T3 (es) 2014-03-12
BRPI0911577B1 (pt) 2021-02-23
ZA201006752B (en) 2011-05-25
KR20100135320A (ko) 2010-12-24
PE20091787A1 (es) 2009-12-14
MY156601A (en) 2016-03-15
CO6300940A2 (es) 2011-07-21
SI2285808T1 (sl) 2014-03-31
HK1149935A1 (en) 2011-10-21
AU2009242279A1 (en) 2009-11-05
US8399453B2 (en) 2013-03-19
KR101390081B1 (ko) 2014-04-29
TWI442921B (zh) 2014-07-01
CN102015711B (zh) 2013-05-01
BRPI0911577B8 (pt) 2021-05-25
ECSP17068127A (es) 2017-10-31
BRPI0911577A2 (pt) 2016-01-05
CA2719365C (en) 2017-03-07
JO2904B1 (en) 2015-09-15
EA201001689A1 (ru) 2011-08-30
US8053442B2 (en) 2011-11-08
MY152021A (en) 2014-08-15
IL208357A0 (en) 2010-12-30
CY1114874T1 (el) 2016-12-14
US20110275613A1 (en) 2011-11-10
EP2285808B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
ECSP17068127A (es) Derivados de espiro-indol para el tratamiento de enfermedades parasitarias
ECSP077894A (es) Antagonistas de npy, preparación y usos
DOP2014000115A (es) Uso de 4-fenil-piridinas sustituidas para la fabricación de medicamentos útiles en el tratamiento de enfermedades relacionadas con el receptor de nk1
HN2011002022A (es) Composicion farmaceutica solida que comprende amlodipina y losartan
CR20120008A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
SMT201600055B (it) Composizione farmaceutica per il trattamento o la prevenzione del glaucoma
UY35146A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
ECSP14017584A (es) Compuestos inhibidores de raf
PE20151065A1 (es) Novedosos derivados de bencimidazol como antagonistas de ep4
UY32848A (es) Compuestos heterocíclicos de oxima
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
CO6771450A2 (es) Ureas asimétricas y usos médicos de las mismas
CR20110209A (es) Composición farmacéutica sólida
CO6321288A2 (es) Sales de compuestos inhibidores de vih
IN2012DN01684A (es)
HN2012001262A (es) Nuevos derivados de 8heterociclo-piperidina condensada)-( piperazinil)-1-alcanona o de (heterociclo-pirrolidina condensada)-(piperazinil)-1-alcanona y su utilizacion como inhibidores de p75
CU24011B1 (es) Piperidinas 2-fenil-5-(1,2,4-oxadiazol-5-il) sustituidas
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
EP2485721A4 (en) APOGOSSYPOLON DERIVATIVES AS ANTICREMENTS
TH93138B (th) อนุพันธ์สไปโร-อินโดลสำหรับการบำบัดโรคจากเชื้อปรสิตสาขาวิทยาการที่เกี่ยวข้องกับการประดิษฐ์
TN2010000458A1 (en) Spiro indole derivatives for the treatment of parasitic diseases
TH106774A (th) อนุพันธ์สไปโร-อินโดลสำหรับการบำบัดโรคจากเชื้อปรสิตสาขาวิทยาการที่เกี่ยวข้องกับการประดิษฐ์
EA201101193A1 (ru) Применение аторвастатин лактолов в качестве лекарственных средств
CU20100011A7 (es) Compuestos orgánicos